World Journal of Gastrointestinal Oncology最新文献

{"title":"Colossal well-differentiated liposarcoma of the small bowel mesentery: A case report.","authors":"Yong Tian, Guo-Qin Liu, Chuan-Fang Li, Qing-Ming Tian, Song Qiao","doi":"10.4251/wjgo.v18.i1.114648","DOIUrl":"https://doi.org/10.4251/wjgo.v18.i1.114648","url":null,"abstract":"<p><strong>Background: </strong>Well-differentiated small bowel mesenteric liposarcoma (LPS) is rare, with high malignancy, poor prognosis, and high preponderance to local recurrence.</p><p><strong>Case summary: </strong>Here we described a 71-year-old male, who complains of persistent abdominal distension for a month. The clinical manifestation is a huge abdominal mass occupying almost the entire abdomen. Physical examination indicated palpable massive mass in the abdomen, hard texture, indefinable boundary, poor mobility. The abdominal enhanced computed tomography at another hospital scan showed multiple abdominal masses originating from the small bowel mesentery. Abdominal and pelvic magnetic resonance imaging at our hospital showed multiple masses in the abdominal and pelvic cavities, indicating that the tumor originated from the mesentery or peritoneum. Results of exploratory laparotomy indicated that the tremendous mass primarily results from the mesentery of the small intestine, occupying the entire abdominal cavity in a polymorphic and lobulated shape. The patient underwent complete surgical resection of the tumor, and the weight of the tumor was approximately 11 kg. The histopathological examination of the resected specimens confirmed the diagnosis of well-differentiated LPS of the small bowel mesentery.</p><p><strong>Conclusion: </strong>Completed surgical resection was cornerstone, and histopathological and molecular confirmations were crucial. The necessity of adjuvant therapy should be phrased as a potential consideration to improve patient's survival time.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"114648"},"PeriodicalIF":2.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Muscle mass correlates with rocuronium distribution volume and guides dose optimization in obese colorectal cancer patients.","authors":"Zhan-Wen Li, Zhe Liu, Sheng-Qun Liu","doi":"10.4251/wjgo.v18.i1.112742","DOIUrl":"https://doi.org/10.4251/wjgo.v18.i1.112742","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Perioperative anesthesia management of obese patients presents significant challenges as traditional total body weight-based dosing fails to achieve optimal anesthetic effects due to altered pharmacokinetic characteristics including abnormal drug distribution and clearance. Rocuronium exhibits markedly different distribution patterns in obese patients, with conventional weight correction methods inadequately addressing individual muscle mass variations that critically influence drug distribution.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To investigate the quantitative relationship between skeletal muscle index (SMI) and rocuronium distribution volume in obese colorectal cancer patients, establish a population pharmacokinetic model, and develop individualized dosing strategies based on muscle mass.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective cohort study was conducted, including 100 obese patients (body mass index ≥ 30 kg/m&lt;sup&gt;2&lt;/sup&gt;) who underwent elective radical colorectal cancer surgery at our hospital from June 2023 to January 2025. Skeletal muscle mass was measured using InBody260 body composition analyzer and SMI was calculated to assess muscle mass, with male SMI &lt; 7.0 kg/m&lt;sup&gt;2&lt;/sup&gt; and female SMI &lt; 5.7 kg/m&lt;sup&gt;2&lt;/sup&gt; as diagnostic criteria for sarcopenia. Plasma rocuronium concentrations were detected by liquid chromatography-tandem mass spectrometry/mass spectrometry, and nonlinear mixed-effect modeling was used to establish population pharmacokinetic modeling. Stepwise regression was used to screen covariates, and dosing regimens were optimized through Monte Carlo simulation. The primary endpoint was targeted plasma concentration achievement rate, and the secondary endpoint was postoperative residual muscle relaxation incidence.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 100 patients, 35 (35.0%) had sarcopenia and 65 (65.0%) did not. Patients in the sarcopenia group were older (64.1 ± 9.8 years &lt;i&gt;vs&lt;/i&gt; 54.2 ± 10.9 years, &lt;i&gt;P&lt;/i&gt; &lt; 0.001) and had significantly lower SMI (6.2 ± 0.8 kg/m&lt;sup&gt;2&lt;/sup&gt; &lt;i&gt;vs&lt;/i&gt; 8.4 ± 1.2 kg/m&lt;sup&gt;2&lt;/sup&gt;, &lt;i&gt;P&lt;/i&gt; &lt; 0.001). SMI showed strong positive correlation with rocuronium steady-state distribution volume (&lt;i&gt;r&lt;/i&gt; = 0.718, &lt;i&gt;P&lt;/i&gt; &lt; 0.001) and moderate negative correlation with clearance (&lt;i&gt;r&lt;/i&gt; = -0.502, &lt;i&gt;P&lt;/i&gt; &lt; 0.001). A two-compartment population pharmacokinetic model was successfully established, with SMI being the most important covariate affecting central compartment distribution volume (△OFV = -41.2, &lt;i&gt;P&lt;/i&gt; &lt; 0.001). Model validation showed bootstrap successful convergence rate of 92.3%, and 92.1% of observed values fell within prediction intervals in predicted concentration versus predicted concentration. The SMI-based individualized dosing regimen improved target exposure achievement rate from 82.0% in traditional regimen to 93.5% (&lt;i&gt;P&lt;/i&gt; = 0.009), and reduced postoperative residual muscle relaxation incidence from 13.0% to 3.5% (&lt;i&gt;P&lt;/i&gt; = 0.018). The sar","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"112742"},"PeriodicalIF":2.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined multidetector computed tomography and gastrointestinal endoscopy for gastric cancer screening, preoperative staging, and lymph node metastasis detection.","authors":"Le-Ping Ye, Yan-Ping Zhang, Gang Chen, Yi-Xian Wu, Cheng-Long He, Dong Wang, Qiao Mei","doi":"10.4251/wjgo.v18.i1.113662","DOIUrl":"https://doi.org/10.4251/wjgo.v18.i1.113662","url":null,"abstract":"<p><strong>Background: </strong>Early screening, preoperative staging, and diagnosis of lymph node metastasis are crucial for improving the prognosis of gastric cancer (GC).</p><p><strong>Aim: </strong>To evaluate the diagnostic value of combined multidetector computed tomography (MDCT) and gastrointestinal endoscopy for GC screening, preoperative staging, and lymph node metastasis detection, thereby providing a reference for clinical diagnosis and treatment.</p><p><strong>Methods: </strong>In this retrospective study clinical and imaging data of 134 patients with suspected GC who were admitted between January 2023 and October 2024 were initially reviewed. According to the inclusion and exclusion criteria, 102 patients were finally enrolled in the analysis. All enrolled patients had undergone both MDCT and gastrointestinal endoscopy examinations prior to surgical intervention. Preoperative clinical staging and lymph node metastasis findings were compared with pathological results.</p><p><strong>Results: </strong>The combined use of MDCT and gastrointestinal endoscopy demonstrated a sensitivity of 98.53%, specificity of 97.06%, accuracy of 98.04%, positive predictive value of 98.53%, and negative predictive value of 97.06% for diagnosing GC. These factors were all significantly higher than those of MDCT or endoscopy alone (<i>P</i> < 0.05). The accuracy rates of the combined approach for detecting clinical T and N stages were 97.06% and 92.65%, respectively, outperforming MDCT alone (86.76% and 79.41%) and endoscopy alone (85.29% and 70.59%) (<i>P</i> < 0.05). Among 68 patients with confirmed GC, 50 (73.53%) were pathologically diagnosed with lymph node metastasis. The accuracy for detecting lymph node metastasis was 66.00% with endoscopy, 76.00% with MDCT, and 92.00% with the combined approach, all with statistically significant differences (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The combined application of MDCT and gastrointestinal endoscopy enhanced diagnostic accuracy for GC, provided greater consistency in preoperative staging, and improved the detection of lymph node metastasis, thereby demonstrating significant clinical utility.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"113662"},"PeriodicalIF":2.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting multi-region 16S sequencing in gastric cancer.","authors":"Liu Luo, Gang Huang, Hua Yang, Hao Chi","doi":"10.4251/wjgo.v18.i1.114708","DOIUrl":"10.4251/wjgo.v18.i1.114708","url":null,"abstract":"<p><p>Wu <i>et al</i> recently applied multi-region 16S rRNA sequencing to characterize the gastric cancer microbiome, demonstrating improved taxonomic resolution and detection sensitivity over conventional single-region approaches. While the study represents a valuable methodological step forward, it remains limited by single-center design, lack of quantitative calibration, and insufficient control for contamination and inter-laboratory variability. This editorial critically appraises these methodological gaps and emphasizes that future efforts must focus on harmonized, consensus-driven workflows to ensure reproducibility and clinical reliability. The translational potential of multi-region 16S lies in moving from descriptive microbial profiling to actionable clinical integration, particularly for recurrence prediction, treatment-response monitoring, and perioperative complication risk assessment. By addressing these methodological, economic, and ethical challenges, the field can advance toward evidence-based and clinically deployable microbiome-guided precision oncology.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"114708"},"PeriodicalIF":2.7,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites.","authors":"Toshihiko Matsumoto, Soma Sugimoto, Reo Omori, Chinatsu Makiyama, Akio Nakasya, Hiroki Nagai, Hisateru Yasui, Reiji Higashi, Akitoshi Sasamoto, Hironaga Satake","doi":"10.4251/wjgo.v18.i1.112944","DOIUrl":"10.4251/wjgo.v18.i1.112944","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy with an immune checkpoint inhibitor is one of the standard regimens for treating advanced gastric cancer (AGC). Ascites and peritoneal dissemination are common complications and poor prognostic factors of AGC; however, reports regarding its efficacy and safety in patients with AGC and massive ascites are limited.</p><p><strong>Aim: </strong>To evaluate the safety and efficacy of nivolumab combined with chemotherapy in patients with AGC and ascites.</p><p><strong>Methods: </strong>We retrospectively collected clinical data from 124 patients with AGC who received chemotherapy plus nivolumab as first-line treatment from July 2017 to December 2024. Based on computed tomography scans, massive or moderate ascites were classified as high ascites burden (HAB), whereas mild or no ascites were classified as low ascites burden.</p><p><strong>Results: </strong>Ascites was detected in 47 patients (38%); 26 (21%) were classified into the HAB group. Patients in the HAB group exhibited a significantly poorer performance status, a higher prevalence of diffuse-type histology, and lower programmed cell death ligand 1 (PD-L1) expression. Combination therapy with FOLFOX and neutropenia was significantly more common in the HAB group. Progression-free survival (PFS) (4.4 months <i>vs</i> 9.3 months, <i>P</i> = 0.0012) and overall survival (OS) (7.3 months <i>vs</i> 21.2 months, <i>P</i> < 0.0001) were significantly poorer in the HAB group. However, an improvement in ascites was observed in 61.5% of patients in the HAB group. PD-L1 expression did not correlate with either PFS or OS in the HAB group.</p><p><strong>Conclusion: </strong>Nivolumab plus chemotherapy demonstrated modest efficacy and acceptable toxicity in patients with AGC and HAB.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"112944"},"PeriodicalIF":2.7,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular mosaic of colorectal cancer: Why one classification system is no longer enough?","authors":"Sunita Ahlawat, Sumanta Das","doi":"10.4251/wjgo.v18.i1.114502","DOIUrl":"https://doi.org/10.4251/wjgo.v18.i1.114502","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Colorectal cancer (CRC) is one of the most molecularly heterogeneous malignancies, with complexity that extends far beyond traditional histopathological classifications. The consensus molecular subtypes (CMS) established in 2015 brought a marked advancement in the taxonomy of CRC, consolidating six classification systems into four novel subtypes, which focus on vital gene expression patterns and clinical and prognostic outcomes. However, nearly a decade of clinical experience with CMS classification has revealed fundamental limitations that underscore the inadequacy of any single classification system for capturing the full spectrum of CRC biology. The inherent challenges of the current paradigm are multifaceted. In the CMS classification, mixed phenotypes that remain unclassifiable constitute 13% of CRC cases. This reflects the remarkable heterogeneity that CRC shows. The tumor budding regions reflect the molecular shift due to CMS 2 to CMS 4 switching, causing further heterogeneity. Moreover, the reliance on bulk RNA sequencing fails to capture the spatial organization of molecular signatures within tumors and the critical contributions of the tumor microenvironment. Recent technological advances in spatial transcriptomics, single-cell RNA sequencing, and multi-omic integration have revealed the limitations of transcriptome-only classifications. The emergence of CRC intrinsic subtypes that attempt to remove microenvironmental contributions, pathway-derived subtypes, and stem cell-based classifications demonstrates the field's recognition that multiple complementary classification systems are necessary. These newer molecular subtypes are not discrete categories but biological continua, thus highlighting that the vast molecular landscape is a tapestry of interlinked features, not rigid subtypes. Multiple technical hurdles cause difficulty in implementing the clinical translation of these newer molecular subtypes, including gene signature complexity, platform-dependent variations, and the difficulty of getting and preserving fresh frozen tissue. CMS 4 shows a poor prognostic outcome among the CMS subtypes, while CMS 1 is associated with poor survival in metastatic cases. However, the predictive value for definitive therapy remains subdued. Looking forward, the integration of artificial intelligence, liquid biopsy approaches, and real-time molecular monitoring promises to enable dynamic, multi-dimensional tumor characterization. The temporal and spatial complexity can only be captured by complementary molecular taxonomies rather than a single, unified system of CRC classification. Such an approach recognizes that different clinical questions - prognosis, treatment selection, resistance prediction - may require different molecular lenses, each optimized for specific clinical applications. This editorial advocates for a revolutionary change from pursuing a single \"best\" classification system toward a diverse approach that welcomes the molecular","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"114502"},"PeriodicalIF":2.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of visceral obesity on postoperative complications and oncological outcomes in elderly patients with colorectal cancer.","authors":"Jie Zhou, Bing-Ping Wang, Ri-Na Su, Shuang Zhang, Yan-Wei Gao","doi":"10.4251/wjgo.v18.i1.109735","DOIUrl":"https://doi.org/10.4251/wjgo.v18.i1.109735","url":null,"abstract":"<p><strong>Background: </strong>Elderly patients with colorectal cancer (CRC) can judge the risk of postoperative complications and oncological outcomes due to visceral obesity, which can provide data reference for the early prediction of prognosis.</p><p><strong>Aim: </strong>To explore the effect of visceral obesity on postoperative complications and oncological outcomes in elderly patients with CRC.</p><p><strong>Methods: </strong>A total of 150 elderly patients who underwent radical surgery for CRC at Inner Mongolia Medical University and Inner Mongolia Autonomous Region People's Hospital from January 2021 to June 2024 were retrospectively analyzed. Patients were divided into the abdominal [visceral fat area (VFA) ≥ 100.00 cm², <i>n</i> = 80] and non-abdominal (VFA < 100.00 cm², <i>n</i> = 70) obesity groups according to the VFA measured by preoperative computed tomography. The two groups showed no significant differences in age, sex, tumor location, tumor-node-metastasis stage, and underlying disease (<i>P</i> > 0.05). All patients underwent standardized laparoscopic assisted surgery and received unified perioperative management. Complications, nutritional status, changes in biochemical indicators, and tumor recurrence and metastasis were evaluated postoperatively.</p><p><strong>Results: </strong>The overall incidence of postoperative complications was significantly higher in the abdominal obesity group than in the non-abdominal obesity group (<i>P</i> < 0.05). The pulmonary infection on postoperative day (POD) 3 (<i>P</i> = 0.038), anastomotic leakage on POD 7 (<i>P</i> = 0.042), and moderate-to-severe complications (Clavien-Dindo class III, <i>P</i> = 0.03) were significantly different. With respect to biochemical indicators, the white blood cell count, neutrophil percentage, and C-reactive protein level in the abdominal obesity group continuously increased after surgery (<i>P</i> < 0.05); the albumin level on POD 1 was even lower (<i>P</i> = 0.024). Regarding tumor markers, carcinoembryonic antigen (<i>P</i> = 0.039) and carbohydrate antigen 19-9 (<i>P</i> = 0.048) levels were significantly higher in the abdominal obesity group at 3 months after surgery, and local recurrence rates were higher than those in the non-abdominal obesity group at 30 days and 3 months after surgery (<i>P</i> < 0.05). Abdominal obesity was an independent risk factor for postoperative complications (odds ratio: 3.843, <i>P</i> = 0.001), overall survival [hazard ratio (HR): 1.937, <i>P</i> = 0.011], and disease-free survival (HR: 1.769, <i>P</i> = 0.018).</p><p><strong>Conclusion: </strong>Visceral obesity significantly increases the risk of postoperative complications in elderly patients with CRC and may adversely affect short-term tumor prognosis. Preoperative risk identification and interventions for abdominal obesity should be strengthened to improve perioperative safety and postoperative rehabilitation quality.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"109735"},"PeriodicalIF":2.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive model based on magnetic resonance imaging for chemotherapy response in colorectal cancer: Toward a radiologic biopsy approach.","authors":"Ilya D Klabukov, Anna Smirnova, Irina Kondrasheva, Denis S Baranovskii, Elena Yatsenko","doi":"10.4251/wjgo.v18.i1.115117","DOIUrl":"https://doi.org/10.4251/wjgo.v18.i1.115117","url":null,"abstract":"<p><p>We read with great interest the investigation of Kang <i>et al</i> related the applications of the multiparametric magnetic resonance imaging-based predictive model for assessing chemotherapy efficacy in colorectal cancer patients with gene mutations. The authors focused on decision-making based on the integration of tumor differentiation, signal intensity ratio, margin distance, and magnetic resonance imaging-detected lymph node metastasis. Indeed, these multiparameter predictive models could also be used for diagnosis as an alternative to invasive tissue examination methods. However, progress in this field enables us to shift the paradigm to radiology biopsies, particularly given the nonlinear effects of various radiation sources.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"115117"},"PeriodicalIF":2.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in radiofrequency ablation for pancreatic cancer.","authors":"Si-Yu Peng, Zong-Yang Li, Hong-Qiao Cai","doi":"10.4251/wjgo.v18.i1.113764","DOIUrl":"https://doi.org/10.4251/wjgo.v18.i1.113764","url":null,"abstract":"<p><p>Radiofrequency ablation (RFA), particularly endoscopic ultrasound-guided RFA (EUS-RFA), has emerged as a promising minimally invasive approach for the treatment of pancreatic cancer, especially in patients with locally advanced or unresectable disease. This review outlines recent technological developments in EUS-RFA, including innovations in energy delivery systems, probe design, and real-time thermal monitoring, which have improved the precision and safety of the procedure. Clinical studies combining EUS-RFA with chemotherapy have demonstrated encouraging outcomes, with improvements in overall survival, progression-free survival, tumor necrosis, and symptom control compared to chemotherapy alone. Additionally, RFA-induced tumor antigen release and modulation of the tumor microenvironment suggest a potential synergistic role with immunotherapy. Despite its promise, the widespread adoption of EUS-RFA is limited by a lack of large-scale randomized controlled trials and standardized treatment protocols.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"113764"},"PeriodicalIF":2.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult liver rhabdomyosarcoma complicated with sarcomatoid carcinoma: A case report.","authors":"Jie-Qun Ma, Chen Wang, Suo-Ni Li, Qi Zheng, Jie Bai, Cai-Xia Ding, Yan-Bing Zhang","doi":"10.4251/wjgo.v18.i1.114745","DOIUrl":"https://doi.org/10.4251/wjgo.v18.i1.114745","url":null,"abstract":"<p><strong>Background: </strong>Rhabdomyosarcoma (RMS) is a type of malignant tumor originating from rhabdomyocytes or mesenchymal cells differentiating into rhabdomyocytes. Hepatic pleomorphic RMS is a rare malignant liver tumor. Hepatic sarcomatoid carcinoma is also a rare epithelial malignant tumor originating from the liver; it is characterized by the coexistence of both carcinomatous and sarcomatoid spindle cell components.</p><p><strong>Case summary: </strong>This paper reports a special case of an elderly woman whose initial liver puncture biopsy showed pleomorphic RMS. After chemotherapy with the vincristine + doxorubicin + cyclophosphamide regimen, the alpha-fetoprotein level increased significantly. Therefore, a second liver puncture was performed, the pathological result of which was hepatic sarcomatoid carcinoma. Next-generation sequencing revealed <i>MET</i> gene amplification with an average copy number of 9 in the tumor tissue; however, both fluorescence <i>in situ</i> hybridization and immunohistochemical tests were negative for MET amplification. The treatment regimen was adjusted to chemotherapy combined with immunotherapy; however, the disease progressed rapidly, and the overall survival was only 6 months.</p><p><strong>Conclusion: </strong>By sharing the diagnosis and treatment process of this patient and reviewing the relevant literature, we aim to help clinicians enhance their understanding of two rare diseases, namely pleomorphic RMS and sarcomatoid carcinoma of the liver.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"18 1","pages":"114745"},"PeriodicalIF":2.5,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}